PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology Corporation (NASDAQ:PDSB) has announced interim safety and immune response data from a Phase 1/2 clinical trial for PDS0301, a novel investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with docetaxel, to treat metastatic prostate cancer. The data will be presented at the 11th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2023) in Athens, Greece.
October 11, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotech's announcement of positive interim data from its Phase 1/2 clinical trial for PDS0301 could potentially boost investor confidence and positively impact the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence as they indicate progress in the company's pipeline. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100